BioSpace News Archive

VIVUS LLC today announced that the U.S. Food and Drug Administration (FDA) approved QSYMIA (phentermine and topiramate extended-release capsules) CIV for use in the treatment of obesity in adolescents (12-17 years old) with an initial body-mass index (BMI) in the 95th percentile or greater standardized for age and sex.

Acuamark Diagnostics (“AcuamarkDx”), an early cancer detection company, today announced the closing of an $11.3 million Series A round.

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today provided an informational update to stockholders regarding its proposed rights offering and the expected key dates and terms relative to the offering.

Navitus Health Solutions , an industry-disrupting pharmacy benefit manager (PBM) that’s committed to bringing humanity to pharmacy benefits management through greater transparency and affordability, announced today that Shayna Schulz has joined the company as Chief Operations Officer.

Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), today announces that the US Food and Drug Administration (FDA), has announced a forthcoming public advisory meeting of the Oncologic Drugs Advisory Committee (ODAC), on September 22, 2022, to discuss the benefit/risk of Pepaxto® (melphalan flufenamide).

The requested amendment and extension is subject to approval from the Exchange.

Masimo (NASDAQ: MASI) today announced the findings of a randomized, controlled trial published in the Journal of Clinical Anesthesia in which Dr. Melody H.Y. Long and colleagues from the KK Women’s and Children’s Hospital in Singapore evaluated the ability of electroencephalogram (EEG)-guided anesthesia, using Masimo SedLine® brain function monitoring, to reduce the amount of the drug sevoflurane needed to maintain anesthesia in pediatric patients undergoing minor surgery.

Forecast to 2030,’ thoroughly examines the Delirium industry to provide essential data & information for the targeted readers.

Forecast to 2030,’ thoroughly examines the Tinnitus Management industry to provide essential data & information for the targeted readers.

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced an upcoming presentation on DecisionDx®-Melanoma, the Company’s risk stratification gene expression profile (GEP) test, at the 2022 American Academy of Dermatology (AAD) Innovation Academy, being held in Vancouver, Canada, July 21-24.